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 Abstract 
Background: Arrhythmogenic Cardiomyopathy (ACM) is an inherited cardiac disease 
characterized by progressive fibro-fatty myocardial replacement, ventricular arrhythmia, heart 
failure and sudden death. Causative mutations can be identified in 60% of patients and most of 
them are found in genes encoding mechanical junction proteins of the intercalated disc (ID). 
Methods: Whole-exome sequencing (WES) was performed on the proband of an ACM family. 
Sanger sequencing was used to screen for mutations the tight junction protein 1 (TJP1) gene in 
unrelated patients. Predictions of local structure content and molecular dynamics simulations 
were performed to investigate the structural impact of the variants.
Results: A novel c.2006A>G p.(Y669C) variant in TJP1 gene was identified by WES in an 
ACM patient. TJP1 encodes zonula occludens 1, an ID protein interacting with proteins of gap 
junctions and area composita. Additional rare TJP1 variants have been identified in 1 out of 40 
Italian probands (c.793C>T p.(R265W)) with arrhythmogenic right ventricular cardiomyopathy 
and in 2 out of 43 Dutch/German patients (c. 986C>T, p.(S329L) and c.1079A>T, p.(D360V)) 
with dilated cardiomyopathy and recurrent ventricular tachycardia. The p.(D360V) variant was 
identified in a proband also carrying the p.(I156N) pathogenic variant in DSP. All 4 TJP1 
variants are predicted to be deleterious and affect highly conserved amino acids, either at the 
guanylate kinase-like (GUK) domain (p.(Y669C)) or at the disordered region of the protein 
between the PDZ2 and PDZ3 domains (p.(R265W), p.(S329L) and p.(D360V)). The local 
unfolding induced by the former promotes structural rearrangements of the GUK domain, 
whereas the others are predicted to impair the function of the disordered region. Furthermore, 
rare variants in TJP1 are statistically enriched in ACM patients relative to controls. 
Conclusions: We provide here the first evidence linking likely pathogenic TJP1 variants to 
ACM. Prevalence and pathogenic mechanism of TJP1-mediated ACM remains to be 
determined. 
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Introduction 
Arrhythmogenic cardiomyopathy (ACM) (MIM #107970) is the second most common cause 
of unexpected sudden death among young people and athletes.1,2 Its main clinical features 
comprise structural and functional abnormalities of the ventricles and ventricular 
arrhythmias.2,3 The subform predominantly involving the right ventricle (ARVC) is the most 
common, even though left and biventricular forms are also well-documented.4,5 
ACM  distinct histopathological profile consists of the progressive replacement of the 
myocardium by fatty or fibrofatty tissue, starting from the epicardium toward the endocardium 
and eventually becoming transmural.6 The disease is familial in about half of the cases and 
typically shows an autosomal dominant inheritance, with reduced penetrance and variable 
expression.7 A genetic cause can be established in about 60% of the patients.8 
The majority of pathogenic variants in ACM have been identified in genes encoding the 
intercalated disc (ID) proteins plakoglobin (JUP)9, desmoplakin (DSP)10, plakophilin-2 
(PKP2)11, desmoglein-2 (DSG2)12, desmocollin-2 (DSC2)13, alpha-T-catenin (CTNNA3)14 and 
N-cadherin (CDH2).15,16 
A few other mutations have been found in non-ID genes encoding cardiac ryanodine receptor 
2 (RYR2)17, transforming growth factor beta 3 (TGF 3)18, transmembrane protein 43 
(TMEM43)19, desmin (DES)20, titin (TTN)21, lamin A/C (LMNA)22, phospholamban 
(PLN)23 and sodium voltage-gated channel alpha subunit 5 (SCN5A).24 
Here we report the identification of likely pathogenic variants in the tight junction protein 1 
(TJP1) gene in patients with ACM, thereby linking pathogenic variants in TJP1 with a human 
disease for the first time. TJP1 encodes for a scaffolding protein, called zonula occludens-1 
(ZO-1), which interacts with various components of cardiac ID. 
 
Materials and Methods 
Raw data, analytic methods, and study materials are available on request from the 
corresponding author, for purposes of reproducing the results or replicating the procedure. The 
study protocol was approved by the ethics committee review board of the University of Padua 
(Padua, Italy) and of the Amsterdam University Medical Center (Amsterdam, The 
Netherlands). 
Methods are available as supplemental data. 
 
Results 
Genetic screening 
Proband II-4 of family A, negative for point mutations and copy number variations (CNVs) in 
the most frequently mutated ACM genes, was screened by whole exome sequencing (WES). 
After the removal of sequencing adapters and trimming of low-quality bases, approximately 25 
Gb of cleaned sequencing bases were obtained. 99.99% of the sequencing reads was aligned to 
the human reference genome (hg19), with 63.17% effective reads from target regions being 
obtained after the removal of PCR duplications. The average sequencing depth was 216.57-
fold, with 98.57% of target regions having at least a 10-fold coverage. 
As a result, 21711 SNPs and 644 InDels were identified. Upon excluding synonymous variants 
outside splicing regulatory sites and predicted benign missense variants, 52 novel or rare 
variants were filtered (Table I in the Data Supplement). TJP1 which 
encodes a multifunctional protein interacting with various components of the cardiac ID called 
ZO-1, resulted the first ranked gene by two different prioritization tools (Figure 1A and Table 
II in the Data Supplement).The p.(Y669C) missense variant was absent from all databases and 
was predicted to be damaging by 8 in silico tools (Figure 1B).This variant has a CADD C-score 
of 25.5 (Figure 1B); of note, a C-score over 20 indicates that it is amongst the top 1% of 
deleterious variants in the human genome. p.(Y669C) affects a highly conserved amino acid at 
the guanylate kinase-like (GUK) domain of ZO-1 (Figure 1C). Sanger sequencing confirmed 
the presence of this heterozygous variant in the proband and in 6 out of 9 family members 
(Figure 2). 
The presence of additional variants in exons with a coverage <15X of known ACM genes was 
excluded by Sanger sequencing . 
Targeted genetic screening of TJP1 in 40 additional Italian ACM patients identified the likely 
pathogenic variant c.793C>T p.(R265W) in the proband of family B. This variant is present in 
gnomAD database with a MAF of 0.001% (2/111550 alleles) in European individuals. It is 
predicted to be damaging by 8 in silico tools and its CADD C-score is 33 (Figure 1B), indicating 
that it is amongst the top 0.1% of deleterious variants in the human genome. This variant affects 
a highly conserved amino acid localized just after the end (at position 261) of the second PDZ 
domain of ZO-1 (Figure 1C). 
To exclude the presence of additional mutations in ACM genes or in other candidate genes, the 
also analyzed by WES. After removing low-quality reads, approximately 
18.2 Gb of cleaned sequencing bases were obtained; 99.98% of the sequencing reads was 
aligned to the human reference genome (hg19), with 62.93% effective reads from target regions 
being obtained after the removal of PCR duplications. The average sequencing depth was 
162.26-fold, with 98.07% of target regions having at least a 10-fold coverage. As a result, 21691 
SNPs and 630 InDels were identified. Among them, 48 variants were filtered as described above 
(Table III in the Data Supplement). Once again, TJP1 resulted the first ranked gene by two 
different prioritization tools (Figure 1A and Table IV in the Data Supplement). The presence 
of additional variants was excluded in all exons of ACM genes with a coverage <15X by Sanger 
sequencing. In family B  (II-3) turned out to also have this variant 
(Figure 2). 
In addition, WES data has been analyzed from an independent cohort of 43 Dutch/German 
patients with a clinical diagnosis of ACM; among them, 11 fulfilled the formal criteria for its 
sub-form ARVC while 32 had a diagnosis of non-ischemic dilated cardiomyopathy (DCM) with 
recurrent sustained ventricular tachycardia (VT). Two missense pathogenic variants in TJP1 (c. 
986C>T, p.(S329L) and c.1079A>T, p.(D360V)) have been identified in two probands. As 
before, TJP1 gene was ranked first by Endeavour in both patients (Figure 1A and Tables VI 
and VII in Data Supplement). The p.(S329L) variant, identified in a proband negative for 
mutations in ACM genes, is present in gnomAD database with a MAF of 0.006% (16/269882 
alleles), and is predicted to be damaging by 6 in silico tools and its CADD C-score is 30 (Figure 
1B). The p.(D360V) variant, identified in a proband carrying also the p.(I156N) pathogenic 
variant in DSP, is absent from all databases, is predicted to be damaging by 5 in silico tools and 
its CADD C-score is 28.5 (Figure 1B). In the absence of additional affected family members, 
we cannot define the pathogenic role of TJP1 and DSP variants. 
Both TJP1 variants affect highly conserved amino acids localized between PDZ2 and PDZ3 
domains. Sanger sequencing confirmed the presence of these heterozygous variants in both 
probands. 
Interestingly, TJP1 showed a probability of being a loss-of-function (LoF) intolerant (pLI) gene 
of 1. extremely LoF intolerant. In gnomAD database 
1160 TJP1 
Among these variants, only 228 were predicted to have a probably-damaging effect and were 
identified in 272 out of 138632 (0.19%) subjects. On the other hand, we identified 4 likely 
pathogenic variants in 4 out of 84 (4.8%) ACM patients, hence showing a significantly higher 
prevalence compared to individuals carrying a rare variant (p=0,0006) and to individuals 
carrying a probably-damaging variant (p=6,1354E-21). 
 
Clinical Data 
Family A was evaluated after the sudden death of a 36 years old man (II-2); a few months 
before, he presented with a syncopal episode during effort. ECG showed negative T waves in 
V1-V3, whereas on a 2D-echocardiogram the right ventricle (RV) was dilated (PLAX RVOT 
= 42 mm; PSAX RVOT = 41 mm) with a reduced systolic function (FAC: 30%) and presence 
of kinetic abnormalities (Table 1 and Table VIII in Data Supplement). Before a cardiac 
magnetic resonance (MRI) was made, he died during effort. Autopsy was performed at another 
hospital leading to a diagnosis of an unspecified cardiomyopathy. Histologic slides, which were 
later reviewed at our center, showed fibro-fatty replacement in the free wall of both ventricles 
together with myocardial atrophy, features in keeping with ACM (Figure 3). The 35 years-old 
brother (II-4) was then evaluated in our outpatient clinic and diagnosed with ACM (Table 1). 
ECG showed intraventricular conduction delay, negative T waves in V1-V5 and low QRS 
voltages (Figure 4A). At 24-hour Holter ECG, frequent premature ventricular contractions 
(PVCs) with left bundle branch block (LBBB) morphology were detected. MRI showed RV 
dilatation with regional kinetic abnormalities; the left ventricle was also dilated with mild 
diffuse hypokinesia. Moreover, late gadolinium enhancement as mid-mural striae was 
detectable in the inferior-lateral wall of left ventricle (Figure 4B). One additional brother (II-9) 
fulfilled the ACM -1) was asymptomatic and 
showed negative T waves in V1-V2, whereas the 2D echo was normal. Finally, subjects III-1, 
III-2 and III-5, who were children at the time of clinical examination, and the remaining 
-6) did not show clinical and instrumental signs of the disease, in 
line with ACM incomplete penetrance (Table 1). 
The proband of family B was a female diagnosed with ACM at the age of 51. She underwent 
cardiac evaluation for palpitations. ECG showed negative T waves in V1-V3 and frequent PVCs 
at 24-hour Holter ECG. 2D-echo revealed a moderated dilatation and dysfunction of the RV 
(Table 1). During the familial screening, the 65 years-old sister was also diagnosed with ACM, 
showing negative T waves in V1-V2 and frequent PVCs with LBBB-morphology. Her 2D-echo 
showed mild RV dilation with normal function (Table 1).  
Proband C carrying the p.(S329L) variant was a male with DCM at the age of 55 years. He 
underwent cardiac evaluation due to progressive dyspnea. His LV ejection fraction was 
estimated at 33%, with a LVED = 76 mm. RV function was considered normal, with just 
moderately depressed contractility. The family history was negative. ECG showed no 
repolarization abnormalities. He was further known with persistent atrial fibrillation, renal 
dysfunction, diabetes and hypertension. At 61 he had an electrical storm that was treated by 
medication. At the age of 62 years he was referred to the hospital for VT ablation due to 
recurrent VTs with ICD shocks. Electro-anatomical mapping revealed an arrhythmogenic 
substrate in the posterior-basal LV epicardium and in the anterior-basal septal endocardium. He 
had VT recurrence after one year. Six months later he received a LVAD due to progression of 
heart failure.   
Proband D, carrying the p.(D360V) variant, was a male with DCM diagnosed at the age of 66. 
He underwent cardiac evaluation due to syncope and documentation of fast VTs with right 
bundle branch block-morphology. LV ejection fraction was estimated at 40% (LVEDD = 67 
mm). RV function was considered normal. The family history was negative. ECG showed no 
repolarization abnormalities. He was further known with diabetes and hypertension. At 73 he 
had an electrical storm and was referred to the hospital for VT ablation. Endocardial electro-
anatomical mapping revealed an arrhythmogenic substrate in the inferior-posterior basal LV 
with a septal extension. At the 2-year follow-up he had no VT recurrence.   
 
In silico prediction of the effects of ZO-1 likely pathogenic variants 
ZO-1 is a multi-domain protein, presenting three consecutive PDZ (PDZ1-3) domains, a SH3 
domain, a guanylate kinase-like (GUK) domain and a ZU5 domain, as reported in the PFAM 
database. Our alignment of 43 orthologous sequences showed that amino acid R265 and the 9 
residues immediately downstream are fully conserved between species. We then checked if the 
structural characteristics of the ZO-1 fragment 265RATLLNVPDL275 could be impaired by the 
pathogenic variant. Predictions of local structure content with FELLS of both wild type and 
mutant suggested that this fragment forms an additional PDZ2 -strand, whereas the p.(R265W) 
variant induces destabilization of this transient strand (Figure 5A).
Both p.(S329L) and p.(D360V) variants localize in an intrinsically disordered linker connecting 
PDZ2 and PDZ3. Multiple sequence alignment shows that the entire region, including the two 
positions, is almost conserved among mammals. The p.(S329L) variant overlaps five putative 
linear motifs (Figure S1 in the Data Supplement); three of them suggest that this region may be 
involved in protein-protein interaction. Similarly, p.(D360V) variant is predicted to overlap 
three linear motifs (Figure S1 in the Data Supplement), two of them suggest that this mutation 
may impair ZO-1 interaction with MAP kinases. However, the prediction confidence is low, 
thus not allowing further speculation about its pathogenic effect. 
The p.(Y669C) likely pathogenic variant is localized within the GUK domain. This 
enzymatically inactive domain is connected to the PDZ3 domain through a SH3 module acting 
as a linker.25 The variant falls at the contact region between strands 2/ 3, which are members 
of a large five -sheet structure which forms the GUK hydrophobic core. We performed a 40 
ns full atom molecular dynamics simulation to investigate the structural impact of the 
p.(Y669C) variant. Analysis of the trajectories showed the wild-type protein to be relatively 
more stable than the mutant. In particular, root mean square deviation (RMSD) analysis showed 
the wild type protein fluctuating around 0.3 nm (Figure 5B). We also observed a short peak of 
0.5 nm between 12 and 18 ns of simulation. Frames inspection revealed that the increase was 
due to the movement of a single loop within residues 586-631. In the same simulation 
conditions, the mutant protein showed a RMSD peak of 0.5 nm, reached after only few ns, 
while the RMSD value remains over 0.4 nm for the entire simulation. Structural comparison 
between the last frame calculated for each run showed that p.(Y669C) could induce a visible 
structural rearrangement of the GUK domain. When superimposed, the proteins showed a 
similar organization for the PDZ3 domain, while the GUK domain resulted to adopt a more 
opened conformation in the mutated protein (Figure 5B). Hence, we propose that increased 
mobility of the GUK domain is compatible with a local unfolding induced by p.(Y669C). A 
network of interacting residues generated with RING around 10 Å from position 669 showed 
that several hydrophobic interactions were lost during the simulation of the mutant protein. In 
particular, p.(Y669C) broke the van der Waals interactions between Y669 and L66, I789, 
promoting a clear structural rearrangement. 
The crystal structure of the ZO-1 N-terminal domain, in which p.(R265W), p.(S329L) and 
p.(D360L) variants are located, is not available. Therefore, a molecular dynamics simulation 
could not be carried out. 
Discussion 
Here we provide the first description of likely pathogenic TJP1 variants identified in patients 
with ACM; no previous association of TJP1 variants to inherited human diseases has been 
reported. The four probands fulfil the current diagnostic criteria for ARVC or had DCM with 
recurrent sustained VTs and three of them resulted negative for pathogenic/likely pathogenic 
variants in all known ACM genes and for CNVs in the most frequently mutated genes. 
Moreover, no additional pathogenic variants have been identified in obvious ACM candidate 
genes by WES analyses. Mutation screening performed in all available family members 
revealed that all affected subjects were mutation carriers. 
TJP1 gene encodes the multifunctional protein ZO-1, which comprises four different domains, 
PDZ, SH3, GUK and ZU5, and interacts with different proteins of the ID. 
This latter is a specialized  in which mechanical and electrical junctions are 
interlinked via protein-protein interactions.26 The ID components were initially described as 
independent; however, it has been demonstrated that in cardiac tissue of higher order 
mammalian species they actively interact and form multiprotein complexes called area 
composita (constituted by proteins of desmosomes and adherens junctions) and connexome 
(constituted by proteins of desmosomes, gap junctions and sodium channel complex).26 
In cardiomyocytes, ZO-1 is essential for a normal organization of both gap junctions (GJs) and 
area composita, interacting with Connexin43 (Cx43) and N-Cadherin respectively.27,28 It has 
been reported that ZO-1 regulates the number, size and distribution of GJs, binding Cx43 
molecules present at the perinexus, an area adjacent to the functional GJs.29,30 Free connexons 
in the perinexus are unable to associate with connexons of neighboring cells as long as ZO-1 is 
bound.26 In ventricles from patients with congestive heart failure, showing GJs remodeling, ZO-
1 protein levels were significantly increased, whereas Cx43 expression was downregulated; the 
proportion of Cx43 interacting with ZO-1 was significantly enhanced, thus suggesting that ZO-
1 prevents the formation of functional GJs.27 Interestingly, Palatinus et al. reported that the 
regulation of functional GJ localization at cell-cell interactions between cardiomyocytes does 
not depend on the ZO-1-Cx43 interaction only, but also on the level of ZO-1 association with 
the N-cadherin in the area composita.28 ZO-1 forms a molecular link between GJs and area 
composita, interacting with Cx43 via the second PDZ domain31 and connecting cadherin to the 
32,33 
Tjp1 knockout mice showed embryonic lethal phenotype associated with massive apoptosis in 
the notochord, neural tube area and allantois, as well as defective yolk sac angiogenesis, hence 
indicating an essential role of Tjp1in early embryonic development. Heterozygous Tjp1+/- mice 
showed no obvious phenotypes, with fertility and growth rates comparable to those of wild-
type mice.34 Moreover, established ZO-1 knockout Madin-Darby canine kidney cells showed 
remarkable changes comparable in myosin organization at cell-cell contacts and an altered 
localization of tight junction proteins. These changes were reversed by trace ZO-1 expression, 
although an excessive ZO-1 level induced an altered shape of cell-cell junctions.35 
The four likely pathogenic missense ZO-1 variants reported in the present study affect highly 
conserved amino acid residues and are predicted as deleterious by at least 5 prediction tools, 
hence suggesting a functional role for these residues. The p.(R265W) pathogenic variant is 
located in a conserved extension of the PDZ2 domain. Due to its localization, formally outside 
the PDZ2, this variant could be considered not relevant for correct PDZ domain folding. 
Previous structural investigation conducted through nuclear magnetic resonance spectroscopy 
has indeed shown that this residue falls in an intrinsically disordered region.36 However, it has 
been described that disordered regions may undergo specific phase transitions depending on 
their amino acid composition and/or binding partners.37 Our predictions of the local structure 
content of both wild type and mutant proteins suggest that the intrinsically disordered fragment 
265RATLLNVPDL275 forms an additional PDZ2 -strand, whereas p.(R265W) variant induces 
its destabilization. Several PDZ domains are known to present extra regulative regions that 
extend over the C-terminus boundary and frequently assume a regulative role, e.g. improving 
domain stability and/or modulating the ligand binding specificity.38,39 As a relevant example, 
PDZ3 of ZO-1 presents itself an accessory C-terminal tail, which acts as both a stabilizer of 
PDZ3/SH3 domain-domain interaction and a ligand binding site.40 Due to the high conservation 
and the results of our in silico investigation, we hypothesize that the p.(R265W) variant could 
impair the regulative function of the PDZ2-C-terminus region. 
The other two likely pathogenic variants p.(S329L) and p.(D360V) localize in a linker region 
connecting PDZ2 and PDZ3 and overlap different putative linear motifs involved in protein-
protein interaction. Large-scale studies of human phosphor-proteome showed that the S329 is 
a phosphorylation site thought to be implicated in embryotic differentiation and cell mitosis.41,42 
One may speculate that p.(S329L) impairs ZO-1 association with an unknown protein 
containing a WW-domain, a modular protein domain that binds to phosphoserine containing 
motifs.43 However, the pathogenic effect of these two variants may be mostly related to a local 
destabilization of the disordered linker, rather than to a specific functional impairment. 
The p.(Y669C) variant falls inside the GUK domain, for which a crystal structure is available.25 
Molecular dynamics simulation revealed that the mutant protein is less stable than the wild-
type, showing a remarkable loss of hydrophobic interactions around the mutated area and a 
more open conformation of the GUK domain. Lye and coworkers presented a structural 
comparative study between ZO-1 and ZO-3, demonstrating that the main difference between 
the two proteins is a more open conformation of the GUK domain in ZO-3.25 This variation in 
conformation between ZO-1 and ZO-3 might explain the inability of ZO-3 to localize to tight 
junctions in the absence of either ZO-1 or ZO-2. Our findings suggest that the local unfolding 
induced by the p.(Y669C) variant promotes a structural rearrangement which forces the ZO-1 
GUK domain to assume a conformation closer to ZO-3. 
Taking into account the localization of the ZO-1 likely pathogenic variants and the role of ZO-
1 in the cardiac ID, we hypothesize that the mutated proteins alter their binding with one or 
more of the main ZO-1 interacting proteins, such as Cx43 or N-cadherin, thus causing a possible 
impairment of the area composita and/or the connexome. In this perspective, the identification 
of ZO-1 pathogenic variants in ACM patients underlines the potential direct involvement in 
ACM pathogenesis not only of the mechanical components of the ID (i.e. area composita and 
desmosome) but also of the electrical ones (gap junction). 
In summary, multiple lines of evidence, such as cardiac expression of TJP1 and function of the 
encoded protein ZO-1, co-segregation of the variants with the phenotype in two families, high 
conservation of involved amino acids and the in silico predictions of pathogenicity and of the 
effects of the variants, suggest a causal relationship between TJP1 pathogenic variants and 
ACM. Therefore, since the prevalence of TJP1 variants in our cohort of ACM patients is just 
below 5%, we propose a systematic screening for this gene to determine the prevalence of 
variants in different cohorts of ACM patients in a research setting. Further studies will be 
needed to better understand the pathogenic effects of these variants, the behavior of the mutant 
ZO-1 proteins in vivo and the molecular mechanism leading to the ACM phenotype. 
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Figures and Figure Legends: 
 
 
Figure 1. TJP1 likely pathogenic variants. A) Schematic representation of variant filtering 
and gene prioritization performed in WES data of the four probands. B) In silico functional 
prediction and conservation scores of TJP1 variants. C) Schematic representation of ZO-1 
protein and localization of identified variants. Multi sequencing alignments showed 
evolutionary conservation of affected residues (highlighted in red) among species. 
 Figure 2. Family pedigrees of patients carrying TJP1 p.(Y669C) and p.(R265W) likely 
pathogenic variants. Arrows indicate the ACM probands. 
 
 
 
 
 Figure 3. Histological findings in the autoptic sample of patient II-2 of family A. Histologic 
slide of the left ventricular free wall showing focal sub-epicardial fibro-fatty replacement in the 
setting of preserved wall thickness (A, trichrome staining; B, haematoxylin-eosin staining).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4. Instrumental findings in the 35-year-old proband of family A carrying p.(Y669) 
likely pathogenic variant. A) Twelve lead ECG shows sinus rhythm, intraventricular 
conduction delay, negative T waves in V1-V5 and low QRS voltages in limb leads. B) Cardiac 
magnetic resonance demonstrated a dilated right ventricle (end-diastolic volume 136 ml/m2) 
with impaired systolic function and focal bulging on the lateral wall (white arrow on diastolic 
frame in image 1 and on systolic frame in image 2). On T1-inversion recovery post-contrast 
sequence late gadolinium enhancement as midmural striae was detectable in the inferior-lateral 
wall of left ventricle on 3-chamber long axis view (3), confirmed in the orthogonal short axis 
view (4) (empty arrows), suggesting a typical finding of arrhythmogenic biventricular 
cardiomyopathy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 5. In silico predictions of effects of ZO-1 variants p.(R265W) and p.(Y669C). A) 
Overview of the putative additional PDZ2 tail. (Top) Multiple sequence alignment of ZO-1 
PDZ2 domain C-terminal flanking region. The extra boundary conserved region is marked with 
a black box, while a blue dot is used to mark the residue corresponding to the human R265. 
(Bottom) Latent local structure predictions from FELLS suggest destabilization of the 
additional PDZ2 -strand. B) Overview and dynamics of ZO-1SH3-GUK domains. (Top) Wild-
type protein is presented in grey, while colored structure represents the p.(Y669C) mutant (front 
and rear views), with green and blue for SH3 and GUK domains respectively. Magenta 
represents the position of Y669, while red is used for the flexible loop within 586-631 residues. 
The superimposition of the last frames (40 ns) obtained after two independent runs of molecular 
dynamics simulation is shown on the right. Relative distances are presented as black arrows. 
Comparative view of the same structures shows a remarkable spatial reorganization of the 
region surrounding the position 669. (Bottom) Weighted RMSD fluctuation for ZO-1 region 
corresponding to the SH3-GUK domains. The two panels represent the variation observed for 
the wild type and p.(Y669C) mutant proteins, respectively. A significant variation in fold 
stability was observed for the mutant protein, which appears less stable than wild-type. 
